---
schema_version: "secwatch.filing_event.v1"
accession: "0000728387-25-000006"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:03:50.586246+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation; no material new information disclosed

## Summary
- Filing reports updated corporate presentation as Exhibit 99.1, but no specific new data or milestones are mentioned.
- Presentation covers 212Pb radiopharmaceutical pipeline for neuroendocrine tumors and melanoma, and manufacturing supply chain.
- No financial results, guidance changes, or regulatory events are presented in the filing or exhibit.
- Updates appear to be routine corporate slides without substantive new disclosures for investors.

## SEC filing metadata
- accession: 0000728387-25-000006
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000072838725000006/0000728387-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000072838725000006/catx-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000728387-25-000006
- JSON: https://secwatch.observer/filing/0000728387-25-000006.json
- Plain text: https://secwatch.observer/filing/0000728387-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.